Original Commodity

Covid-19 Vaccine Effectiveness against the Omicron (B.i.1.529) Variant

List of authors.
  • Nick Andrews, Ph.D.,
  • Julia Stowe, Ph.D.,
  • Freja Kirsebom, Ph.D.,
  • Samuel Toffa, Ph.D.,
  • Tim Rickeard, M.Sc.,
  • Eileen Gallagher, Ph.D.,
  • Charlotte Gower, D.Phil.,
  • Meaghan Kall, M.Sc.,
  • Natalie Groves, M.Sc.,
  • Anne-Marie O'Connell, M.Sc.,
  • David Simons, M.B., B.S.,
  • Paula B. Blomquist, M.Sc.,
  • Asad Zaidi, M.Sc.,
  • Sophie Nash, M.Sc.,
  • Nurin Iwani Binti Abdul Aziz, M.Sc.,
  • Simon Thelwall, Ph.D.,
  • Gavin Dabrera, M.B., B.S., F.F.P.H.,
  • Richard Myers, M.R.C.P.C.H.,
  • Gayatri Amirthalingam, M.F.P.H.,
  • Saheer Gharbia, Ph.D.,
  • Jeffrey C. Barrett, D.Phil.,
  • Richard Elson, M.Sc.,
  • Shamez N. Ladhani, Ph.D., M.R.C.P.C.H.,
  • Neil Ferguson, D.Phil.,
  • Maria Zambon, Ph.D., F.R.C.Path.,
  • Colin Due north.J. Campbell, M.P.H., F.F.P.H.,
  • Kevin Brown, M.R.C.P., F.R.C.Path.,
  • Susan Hopkins, F.R.C.P., F.F.P.H.,
  • Meera Chand, M.R.C.P., F.R.C.Path.,
  • Mary Ramsay, M.B., B.Southward., F.F.P.H.,
  • and Jamie Lopez Bernal, Ph.D., Chiliad.B., B.S.

Abstract

Background

A rapid increment in coronavirus disease 2019 (Covid-nineteen) cases due to the omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus ii in highly vaccinated populations has aroused concerns about the effectiveness of current vaccines.

Methods

We used a test-negative case–control pattern to approximate vaccine effectiveness against symptomatic disease acquired by the omicron and delta (B.1.617.ii) variants in England. Vaccine effectiveness was calculated after primary immunization with two doses of BNT162b2 (Pfizer–BioNTech), ChAdOx1 nCoV-19 (AstraZeneca), or mRNA-1273 (Moderna) vaccine and later a booster dose of BNT162b2, ChAdOx1 nCoV-nineteen, or mRNA-1273.

Results

Between November 27, 2021, and Jan 12, 2022, a full of 886,774 eligible persons infected with the omicron variant, 204,154 eligible persons infected with the delta variant, and 1,572,621 eligible test-negative controls were identified. At all fourth dimension points investigated and for all combinations of primary course and booster vaccines, vaccine effectiveness against symptomatic disease was higher for the delta variant than for the omicron variant. No effect against the omicron variant was noted from twenty weeks later on two ChAdOx1 nCoV-xix doses, whereas vaccine effectiveness after two BNT162b2 doses was 65.five% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to eight.8% (95% CI, 7.0 to ten.five) at 25 or more weeks. Among ChAdOx1 nCoV-19 principal course recipients, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) at ii to 4 weeks afterward a BNT162b2 booster earlier decreasing to 39.vi% (95% CI, 38.0 to 41.one) at ten or more weeks. Among BNT162b2 chief course recipients, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) at ii to 4 weeks after a BNT162b2 booster earlier declining to 45.7% (95% CI, 44.7 to 46.7) at 10 or more weeks. Vaccine effectiveness later a ChAdOx1 nCoV-xix master course increased to 70.1% (95% CI, 69.v to 70.vii) at 2 to four weeks subsequently an mRNA-1273 booster and decreased to 60.9% (95% CI, 59.seven to 62.ane) at 5 to 9 weeks. After a BNT162b2 main course, the mRNA-1273 booster increased vaccine effectiveness to 73.9% (95% CI, 73.i to 74.6) at ii to 4 weeks; vaccine effectiveness fell to 64.iv% (95% CI, 62.half-dozen to 66.1) at 5 to nine weeks.

Conclusions

Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time. (Funded by the U.One thousand. Health Security Agency.)

Introduction

On Nov 26, 2021, the Globe Health Arrangement Technical Informational Group on SARS-CoV-2 Virus Evolution named the severe astute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 variant, first detected in Botswana and Due south Africa, as the omicron variant of business.1 This classification was based on a rapid increase in confirmed cases of SARS-CoV-two infection in Due south Africa, coinciding with an increase in detections of the omicron variant, identification of a number of worrisome mutations, and early bear witness of an increased risk of reinfection amid recently infected persons.

A large number of mutations have been identified in the omicron variant, including multiple mutations in the receptor-binding domain of the fasten protein that accept been associated with increased transmissibility and immune evasion after natural infection and vaccination.two Emerging laboratory data bespeak a substantially reduced neutralizing antibody response to the omicron variant every bit compared with the original strain of SARS-CoV-2 or the delta (B.ane.617.ii) variant in vaccinated persons, although booster doses improved neutralizing action.3-5 Neutralizing antibodies correlate with protection against reinfection and vaccine effectiveness against infection; therefore, reduced vaccine effectiveness confronting the omicron variant is anticipated on the footing of these early laboratory findings.6-eight

Coronavirus disease 2019 (Covid-19) vaccines are highly constructive confronting symptomatic disease and, more than so, against severe affliction and fatal outcomes caused past the original strain of SARS-CoV-two as well as the alpha (B.one.i.7) variant that predominated in early 2021.9-15 Modest reductions in vaccine effectiveness against infection and balmy disease have been observed with the beta (B.i.351) and delta variants, although effectiveness against severe affliction has remained high for at least half-dozen months after primary immunization with two Covid-19 vaccine doses.xvi-19 Waning of protection has been observed with time since vaccination, specially with the delta variant, which is able to at to the lowest degree partially evade natural and vaccine-induced immunity.20 However, tertiary (booster) doses provide a rapid and substantial increment in protection against both mild and severe disease.19,21-25

In the United kingdom of great britain and northern ireland, cases of infection with the omicron variant were first identified in mid-November 2021 through whole-genome sequencing of polymerase-chain-reaction (PCR)–positive swab samples. Initially, cases occurred primarily in travelers and their close contacts, but customs transmission was apparent first in late November.26 The U.K. Covid-19 vaccination program has been in place since December 2020 with primary courses of ii doses of BNT162b2 (Comirnaty, Pfizer–BioNTech), ChAdOx1 nCoV-nineteen (Vaxzevria, AstraZeneca), or mRNA-1273 (Spikevax, Moderna) vaccine. 2-dose vaccine uptake is more than 60% in all cohorts of persons who are xx years of age or older and more than 80% in all cohorts of persons who are 50 years of age or older, with vaccinations now being offered to children 12 years of age or older.27 Booster vaccination with either BNT162b2 vaccine or a one-half dose (l μg) of mRNA-1273 vaccine was introduced in September 2021 to adults fifty years of historic period or older and those in at-risk groups and was expanded in November 2021 to all adults. Initially, boosters were offered 6 months afterwards completion of the primary grade. With the emergence of the omicron variant in late November 2021, this interval was reduced to 3 months.28

In this study, we estimated vaccine effectiveness against symptomatic disease caused by the delta and omicron variants after 2 doses (primary immunization) of BNT162b2, mRNA-1273, or ChAdOx1 nCoV-nineteen vaccine and afterwards homologous or heterologous booster doses with the same three vaccines.

Methods

Written report Design

We used a test-negative case–command design to judge vaccine effectiveness confronting symptomatic Covid-19 acquired by the omicron variant as compared with the delta variant in persons eighteen years of age or older.17 The odds of vaccination in persons with symptomatic, PCR-positive cases of SARS-CoV-ii infection were compared with those in symptomatic persons who tested negative for SARS-CoV-2 in England.

Data Sources

Covid-19 Testing Information

PCR testing for SARS-CoV-2 in England is undertaken by infirmary and public health laboratories (Pillar 1) as well as by customs testing (Pillar ii). Pillar 2 testing is available to anyone with symptoms consistent with Covid-19 (high temperature, new continuous cough, or loss or change in sense of smell or sense of taste), anyone who is a contact of a person with a confirmed case, care home staff and residents, and persons with a positive rapid lateral-flow antigen test. Lateral-menses tests are freely available to all members of the population for regular home testing. Data on all positive PCR and lateral-flow tests, and on negative Pillar 2 PCR tests from persons with a appointment of onset of Covid-xix symptoms after November 25, 2020, were extracted up to January 12, 2022 (Fig. S1 in the Supplementary Appendix, available with the total text of this commodity at NEJM.org). Persons who reported symptoms and were tested in Pillar 2 between Nov 27, 2021, and Jan 12, 2022, were included in the analysis.

Whatever negative tests taken within 7 days after a previous negative exam, and any negative tests for which the symptom-onset date was inside the 10 days after a previous symptom-onset appointment for a negative test, were dropped considering these probably represented the aforementioned episode. Negative tests taken within 21 days before a subsequent positive examination were likewise excluded because chances were high that these were false negatives. Positive and negative tests within 90 days after a previous positive exam were also excluded; notwithstanding, when participants had afterward positive tests inside 14 days after a positive test, preference was given to PCR tests and tests from symptomatic persons. For persons who had more than than one negative exam, i test was selected at random in the study period. Data were restricted to persons who had reported symptoms and gave a symptom-onset date within the x days earlier testing to business relationship for reduced PCR sensitivity beyond this flow in an infection event. Only positive tests with sequencing or genotyping information or data on fasten cistron (South) target–negative status (indicative of probable omicron infection) were included in the final analysis. A minor number of positive tests were excluded when sequencing showed neither the delta nor the omicron variant. Finally, only samples obtained on November 27, 2021, or after were retained for analysis because this corresponded to the catamenia when S target–negative status was predictive of the omicron variant.

Vaccination Data

The National Immunization Direction Organization (NIMS) contains demographic information on all persons residing in England who are registered with a full general practice physician in that country and is used to record all Covid-19 vaccinations.29 The NIMS was accessed on January 18, 2022, for dates of vaccination and vaccine manufacturer, sex, appointment of birth, race or ethnic grouping, and residential address. Addresses were used to determine the index of multiple deprivation (a national indication of level of impecuniousness that is based on small geographic areas of residence, assessed in quintiles) and were also linked to Care Quality Committee–registered care homes with the use of the unique property-reference number. Data on geographic region (NHS region), clinical hazard-group condition, status of beingness in a clinically extremely vulnerable group, and health and social care worker status were also extracted from the NIMS. Clinical risk groups included a range of chronic conditions as described in the Green Book,thirty whereas the clinically extremely vulnerable group included persons who were considered to be at the highest chance for astringent Covid-19, including those with immunosuppressed conditions and those with severe respiratory affliction.31 Booster doses were identified as a 3rd dose given at least 175 days subsequently a second dose and administered subsequently September 13, 2021. Persons with four or more doses of vaccine, a heterologous primary schedule, or fewer than 19 days betwixt their first dose and 2nd dose were excluded.

Identification of Variants and Assignment to Cases

Sequencing of PCR-positive samples was undertaken through a network of laboratories, including the Wellcome Sanger Institute. Whole-genome sequences were assigned to U.K. Wellness Security Agency definitions of variants on the basis of mutations.32,33 S target condition on PCR testing is an alternative approach for identifying each variant considering the omicron variant has been associated with S target–negative results on PCR testing with the TaqPath analysis, whereas the delta variant nigh always has an S target–positive outcome.26 Approximately 40% of Colonnade ii community testing in England is carried out by laboratories using the TaqPath assay (Thermo Fisher Scientific). Cases were defined every bit being due to the delta or omicron variant on the footing of whole-genome sequencing, genotyping, or S target condition, with sequencing taking priority, followed past genotyping. When subsequent positive tests within 14 days included sequencing or genotyping information or information on S target–negative condition, this data was used to classify the variant. A priori, nosotros considered that S target–negative status would be used to ascertain the omicron variant when the variant accounted for at to the lowest degree 80% of S target–negative cases. Beginning on Jan x, 2022, delta cases were identified by sequencing and genotyping only because the positive predictive value of South target–negative status to identify the delta variant had decreased and could no longer be used.

Testing data were linked to the NIMS on January 18, 2021, through combinations of the unique individual NHS number, date of birth, surname, first name, and postal code with the use of deterministic linkage. A total of 91.eight% of eligible tests could exist linked to the NIMS.

Statistical Assay

Logistic regression was used, with the PCR test upshot as the dependent variable and example participants being those testing positive (stratified in separate analyses as being infected with either the omicron or delta variant) and controls existence those testing negative. Vaccination condition was included as an independent variable, and effectiveness was defined as i minus the odds of vaccination in case participants, divided by the odds of vaccination in controls.

Vaccine effectiveness was adjusted in logistic-regression models for historic period (18 to 89 years in 5-year bands, and so everyone ≥xc years), sex, alphabetize of multiple deprivation (quintile), race or ethnic group, history of strange travel, geographic region, period (twenty-four hour period of test), health and social care worker status, clinical gamble-group status, status of being in a clinically extremely vulnerable group, and previously testing positive. These factors were all considered potential confounders then were included in all models.

Analyses were stratified according to primary immunization course (ChAdOx1 nCoV-nineteen, BNT162b2, or mRNA-1273 vaccine). Whatsoever heterologous primary schedules were excluded.

Vaccine effectiveness was assessed for each primary course in intervals of 2 to 4, 5 to 9, 10 to fourteen, xv to 19, twenty to 24, and 25 or more than weeks after the 2d dose. Vaccine effectiveness was assessed at 2 to 4, 5 to nine, and 10 or more weeks afterwards a BNT162b2 or mRNA-1273 booster after a ChAdOx1 nCoV-19 or BNT162b2 master course. In addition, the ChAdOx1 nCoV-19 booster was assessed afterwards a ChAdOx1 nCoV-19 primary course in these postvaccination intervals. In persons with an mRNA-1273 primary course, vaccine effectiveness was assessed later BNT162b2 or mRNA-1273 booster vaccines afterward 1 calendar week and after ii to 4 weeks.

Results

Descriptive Characteristics

Within sequenced cases from Colonnade 2 testing for which S target testing was performed, the percent of S target–negative tests that were sequenced as the omicron variant was 50% (half dozen of 12) on November 25, 2021; 65% (13 of 20) on Nov 26; ninety% (18 of twenty) on Nov 27; 91% (10 of 11) on November 28; and 89% (17 of 19) on Nov 29. We therefore used cases tested on or subsequently November 27, when the positive predictive value was more 80%.

Characteristics of Persons Tested for SARS-CoV-2 in England, Co-ordinate to Exam Positivity or Negativity and Variant. Vaccination Status of Persons Tested for SARS-CoV-2 in England, According to Test Positivity or Negativity and Variant.

A total of 886,774 persons with symptomatic affliction who were infected with the omicron variant were identified during the study catamenia past sequencing or genotyping or by S target–negative status, and their tests were linked to the NIMS for vaccination status. During the same catamenia, 204,154 eligible persons infected with the delta variant and 1,572,621 eligible test-negative controls were identified (Fig. S2). The characteristics of the persons tested are shown in Table 1, and vaccination status according to exam result is shown in Table 2. The distribution according to sexual practice, geographic region, and race or ethnic group was similar to that in the full national Covid-19 case data, although in that location was a college proportion of young adults (Tabular array S1). Infection with the omicron variant 14 or more days after a booster occurred a median of 39 days (range, 14 to 118) afterwards the booster.

Vaccine Effectiveness, Delta Variant

Vaccine Effectiveness against Symptomatic Disease Caused by the Delta and Omicron Variants, According to the Menses after the Second and Booster Doses.

B.1.617.2 is the delta variant, and B.ane.1.529 the omicron variant, of the severe acute respiratory syndrome coronavirus 2. 𝙸 bars signal 95% conviction intervals.

 Vaccine Effectiveness against Symptomatic Disease Caused by the Delta and Omicron Variants.

Vaccine effectiveness against symptomatic disease in persons who received a master course of the ChAdOx1 nCoV-19, BNT162b2, or mRNA-1273 vaccine according to period after primary immunization with second doses and subsequently a third dose with BNT162b2 or mRNA-1273 is shown in Figure 1 and Tabular array 3 and S2. With the delta variant, vaccine effectiveness later 2 doses of ChAdOx1 nCoV-19 main course started at 82.8% (95% confidence interval [CI], 74.5 to 88.iv) later on 2 to 4 weeks simply waned to 43.5% (95% CI, 42.4 to 44.v) after 25 or more weeks. With the messenger RNA (mRNA) vaccines, effectiveness afterward 2 doses was college in all periods, but there was likewise prove of waning. After a booster with an mRNA vaccine, vaccine effectiveness reached more than 95% with any of the primary courses and remained high up to the longest follow-upwardly points (maximum, ≥x weeks).

Vaccine Effectiveness, Omicron Variant

Vaccine effectiveness was lower for the omicron variant than for the delta variant at all intervals after vaccination and for all combinations of primary courses and booster doses investigated. Among those who had received two ChAdOx1 nCoV-19 doses, most no protective effect of vaccination against symptomatic disease caused by the omicron variant was noted from twenty to 24 weeks after the 2nd dose. Among those who had received two BNT162b2 doses, vaccine effectiveness was 65.five% (95% CI, 63.9 to 67.0) 2 to 4 weeks after the 2d dose, dropping to fifteen.4% (95% CI, 14.2 to 16.vi) after xv to 19 weeks and dropping further to 8.8% (95% CI, 7.0 to ten.five) after 25 or more weeks. The vaccine effectiveness of 2 doses of mRNA-1273 vaccine had a similar reduction over fourth dimension from 75.i% (95% CI, lxx.8 to 78.vii) after two to iv weeks to 14.9% (95% CI, iii.9 to 24.7) later on 25 or more than weeks.

Amidst persons who received ChAdOx1 nCoV-19 every bit the primary course, from 2 to four weeks later a BNT162b2 booster dose, vaccine effectiveness increased to 62.4% (95% CI, 61.8 to 63.0) before waning to 39.6% (95% CI, 38.0 to 41.one) subsequently 10 or more weeks. The mRNA-1273 booster vaccine increased effectiveness to 70.1% (95% CI, 69.v to seventy.vii) later 2 to iv weeks. This waned to threescore.9% (95% CI, 59.7 to 62.1) afterward v to 9 weeks. Vaccine effectiveness was everyman among those who received a ChAdOx1 nCoV-nineteen primary course with a ChAdOx1 nCoV-19 booster vaccine. Waning efficacy was most notable against the omicron variant, for which the vaccine effectiveness was 46.7% (95% CI, 34.3 to 56.7) at 5 to 9 weeks.

Among persons who received BNT162b2 as the primary course, from 2 to 4 weeks later a BNT162b2 booster dose, vaccine effectiveness increased to 67.2% (95% CI, 66.5 to 67.8) before declining to 45.vii% (95% CI, 44.7 to 46.7) later on x or more weeks. The mRNA-1273 booster increased vaccine effectiveness to 73.nine% (95% CI, 73.1 to 74.6) after 2 to 4 weeks before decreasing to 64.four% (95% CI, 62.vi to 66.1) after 5 to 9 weeks. After an mRNA-1273 primary course, vaccine effectiveness increased to 64.9% (95% CI, 62.iii to 67.three) at 2 to 4 weeks later a BNT162b2 booster and 66.3% (95% CI, 63.7 to 68.viii) at 2 to 4 weeks after an mRNA-1273 booster.

Discussion

Our findings indicate that vaccine effectiveness against symptomatic disease caused past the omicron variant is substantially lower than with the delta variant. After two doses, vaccine effectiveness waned apace, with very limited vaccine furnishings seen from 20 weeks after the second dose of whatever vaccine. Booster doses resulted in a substantial increment in protection against mild infection; however, waning of protection against symptomatic affliction was besides seen after booster doses. We are unable to make up one's mind protection against astringent forms of disease using the examination-negative example–control method here owing to the modest number of omicron cases resulting in hospitalization so far in our data set and the natural lag between infection and more severe outcomes. Previous experience with the delta variant in the United Kingdom suggested that protection against hospitalization after ii doses of vaccine was well maintained.19

These findings are consequent with neutralization data for the omicron variant. South African, German, and U.M. studies indicate a reduction in neutralizing activeness by a factor of 20 to forty in serum specimens obtained from recipients of two doses of BNT162b2 as compared with neutralization against early pandemic viruses and by a gene of at least 10 as compared with neutralization against the delta variant.3-five,34 In serum specimens obtained from recipients of two doses of ChAdOx1 nCoV-nineteen, a greater reduction in neutralizing activeness was observed, with a loftier proportion of postvaccination serum samples having neutralizing activity below the limit of quantification in the assay.34 Higher neutralizing activity was observed afterward a booster dose.3,4,34

Although a correlation betwixt neutralizing antibody levels and vaccine effectiveness against symptomatic SARS-CoV-2 infection has been observed at a population level,6 a similar correlation with effectiveness against severe affliction is much less certain. With previous variants, vaccine effectiveness against severe disease, including hospitalization and expiry, has been higher and has been retained for a longer period than effectiveness against mild disease.16,19 Cellular immune responses are likely to play a relatively more important function in protection as antibodies wane with time since infection or vaccination; antibiotic waning may increment the risk of SARS-CoV-2 infection even as cellular immunity probably limits progression to severe disease.35 Cellular amnesty is also likely to play an important role in protection against SARS-CoV-two variants.35 Estimating effectiveness against severe disease acquired by the omicron variant volition follow a lag; however, on the ground of feel with other variants and early estimates of hospitalization rates, vaccine effectiveness against astringent disease is probable to be substantially higher than the estimates against symptomatic disease.19,36

The populations that have received different vaccines equally a primary course are unlike. For example, ChAdOx1 nCoV-19 was the principal vaccine used early in the program in care homes and among persons in clinical take a chance groups. Furthermore, mRNA vaccines were the main vaccines used in persons younger than 40 years of age after the reported association between ChAdOx1 nCoV-nineteen and vaccine-induced thrombotic thrombocytopenia.37 Although adjustments were fabricated for age and clinical risk factors, these age differences may explain some of the differences in the findings for the primary course — for instance, the high vaccine effectiveness confronting omicron ii to 9 weeks after the 2nd dose of BNT162b2 is likely to be primarily among recently vaccinated young adults and teenagers. Differences are also noted in populations that accept received a booster dose every bit compared with those who have received simply two doses, with the onetime skewed toward older populations with more coexisting weather. Persons who have not withal received a booster could accept missed the boost for reasons that may be associated with exposure risk; for instance, booster vaccination may take been delayed owing to an outbreak in a airtight setting. The analysis with ChAdOx1 nCoV-nineteen boosters is particularly likely to be subject to bias because this vaccine was not recommended as a booster in the United Kingdom; therefore, some misclassification may take occurred, and persons who received ChAdOx1 nCoV-xix are likely to have done then because of contraindications to other vaccines.

The large scale of testing and sequencing in the Great britain, besides every bit the use of a national vaccination annals, has enabled rapid evaluation of vaccine effectiveness against symptomatic infection with the omicron variant. However, the study has some limitations, and findings should be interpreted with caution. During this early flow of apportionment of the new variant, a large proportion of cases occurred amongst travelers. Persons who reported strange travel in the preceding 2 weeks were excluded from this analysis; notwithstanding, not all travelers may have been excluded, and contacts of travelers volition not have been identified. This group is probable to have dissimilar exposure than the wider population and may also have different levels of vaccine coverage. Therefore, residual confounding may exist nowadays. Attributable to the relatively pocket-sized number of omicron cases in the United kingdom of great britain and northern ireland, our estimates are field of study to considerable incertitude, and we are unable to break downwards estimates according to population characteristics that may affect vaccine effectiveness (due east.yard., historic period and clinical hazard group).nineteen

In this analysis, our comparator grouping is unvaccinated persons, who brand upward a very small proportion of persons in several age cohorts. These persons are likely to differ from the full general population co-ordinate to characteristics that could confound our estimates of vaccine effectiveness. In this analysis that covers all ages, this type of confounding may be less of an result than in analyses restricted to elderly populations. Furthermore, recent analyses using different command groups take shown good cyclopedia betwixt analyses using an unvaccinated command group and analyses estimating relative vaccine effectiveness among persons who take received a booster dose as compared with those who have received two doses. Booster doses have only recently been rolled out in England; therefore, nosotros are able to approximate vaccine effectiveness for just a short period afterward booster vaccination, and nosotros do not take information on the elapsing of protection later on a booster dose. Some misclassification may also have occurred owing to both imperfect sensitivity and specificity of PCR testing, every bit well equally the apply of Southward target–negative condition to place omicron cases.

Our findings point that two doses of vaccination with BNT162b2 or ChAdOx1 nCoV-19 are insufficient to requite acceptable levels of protection against infection with the omicron variant and mild affliction. Boosting with BNT162b2 or mRNA-1273 provided a substantial increase in protection confronting balmy disease, although waning occurred over time. Boosters will probably offering fifty-fifty greater levels of protection confronting severe and fatal disease. Our findings support maximizing coverage with third doses of vaccine in highly vaccinated populations such as in the United Kingdom. Further follow-up will be needed to appraise protection against severe disease and the duration of protection later booster vaccination.

Funding and Disclosures

Supported by the U.K. Health Security Agency (UKHSA). Dr. Simons is supported by a doctoral training grant from the Biotechnology and Biological Sciences Research Quango (grant number BB/M009513/1).

Disclosure forms provided by the authors are available with the total text of this commodity at NEJM.org.

Drs. Andrews and Stowe contributed equally to this commodity.

Surveillance of coronavirus affliction 2019 (Covid-19) testing and vaccination is undertaken under Regulation three of the Wellness Service (Command of Patient Information) Regulations 2002 to collect confidential patient information (world wide web.legislation.gov.united kingdom of great britain and northern ireland/uksi/2002/1438/regulation/3/made) under Sections 3(i) (a) to (c), 3(i)(d) (i) and (2), and 3. The study protocol was subject to an internal review by the Public Health England Research Ideals and Governance Group and was found to be fully compliant with all regulatory requirements. Given that no regulatory bug were identified and that ideals review is non a requirement for this type of work, it was decided that a total ethics review would not be necessary.

This article was published on March 2, 2022, at NEJM.org.

We thank the UKHSA Covid-19 Data Science Team and the UKHSA Outbreak Surveillance Team and the staff of NHS England, NHS Digital, and NHS Test and Trace for their roles in developing and managing the Covid-19 testing, variant identification, and vaccination systems and data sets as well every bit the reporting NHS vaccinators and the staff of NHS laboratories, UKHSA laboratories, and lighthouse laboratories; the staff of the Wellcome Sanger Institute and other laboratories involved in whole-genome sequencing of Covid-nineteen samples; and the members of the Joint Committee on Vaccination and Immunisation and the U.K. Variant Technical Group for communication and feedback in developing this study.

Writer Affiliations

From the U.Yard. Health Security Agency (N.A., J.S., F.K., S. Toffa, T.R., E.G., C.Thousand., Yard.K., N.Thousand., A.-Yard.O., D.Southward., P.B.B., A.Z., S.N., Due north.I.B.A.A., Southward. Thelwall, G.D., R.One thousand., G.A., S.G., R.E., S.N.50., M.Z., C.Northward.J.C., K.B., Southward.H., Thousand.C., M.R., J.L.B.), the National Establish for Health Inquiry (NIHR) Wellness Protection Enquiry Unit in Vaccines and Immunisation, London Schoolhouse of Hygiene and Tropical Medicine (Due north.A., G.A., C.N.J.C., K.B., M.R., J.L.B.), the Paediatric Infectious Diseases Research Group, St. George's University of London (R.Chiliad., Southward.N.L.), the Medical Research Council Centre for Global Communicable diseases Analysis (N.F.) and the NIHR Wellness Protection Research Unit in Respiratory Infections (N.F., Thou.Z., J.L.B.), Imperial College London, and Guy's and St. Thomas'due south Hospital NHS Trust (K.C.), London, Wellcome Sanger Institute, Hinxton (J.C.B.), and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) — all in the United kingdom of great britain and northern ireland.

Dr. Lopez Bernal tin exist contacted at [electronic mail protected] or at the U.One thousand. Health Security Agency, 61 Colindale Ave., London, NW9 5EQ, United Kingdom.

Supplementary Material

References (37)

  1. 1. Globe Wellness Organization. Nomenclature of omicron (B.1.ane.529): SARS-CoV-two variant of concern. November 26, 2021 (https://www.who.int/news/detail/26-xi-2021-nomenclature-of-omicron-(b.1.one.529)-sars-cov-ii-variant-of-business concern).

  2. ii. European Heart for Disease Prevention and Control. Implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of business (omicron) for the EU/EEA — first update. December two, 2021 (https://www.ecdc.europa.european union/sites/default/files/documents/threat-cess-covid-nineteen-emergence-sars-cov-ii-variant-omicron-december-2021.pdf).

  3. iii. Cele Due south, Jackson 50, Khoury DS, et al. SARS-CoV-2 omicron has all-encompassing but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. Dec 17, 2021 (https://www.medrxiv.org/content/ten.1101/2021.12.08.21267417v3). preprint.

  4. four. Wilhelm A, Widera M, Grikscheit Grand, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. December 13, 2021 (https://www.medrxiv.org/content/x.1101/2021.12.07.21267432v4). preprint.

  5. 5. Dejnirattisai Due west, Huo J, Zhou D, et al. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. December 22, 2021 (https://www.biorxiv.org/content/x.1101/2021.12.03.471045v2). preprint.

  6. half-dozen. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205-1211.

  7. 7. Addetia A, Crawford KHD, Dingens A, et al. Neutralizing antibodies correlate with protection from SARS-CoV-ii in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol 2020;58(eleven):e02107-20-e02107-20.

  8. 8. Jeffery-Smith A, Rowland TAJ, Patel Yard, et al. Reinfection with new variants of SARS-CoV-2 subsequently natural infection: a prospective observational accomplice in 13 care homes in England. Lancet Healthy Longev 2021;2(12):e811-e819.

  9. 9. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. Due north Engl J Med 2020;383:2603-2615.

  10. x. Voysey G, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-two: an acting analysis of 4 randomised controlled trials in Brazil, Due south Africa, and the Great britain. Lancet 2021;397:99-111.

  11. 11. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416.

  12. 12. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and bloodshed in older adults in England: test negative example-control study. BMJ 2021;373:n1088-n1088.

  13. 13. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort report. Lancet 2021;397:1725-1735.

  14. fourteen. Thompson MG, Burgess JL, Naleway AL, et al. Acting estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — eight U.S. locations, Dec 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495-500.

  15. xv. Dagan Northward, Barda Due north, Kepten Eastward, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. Due north Engl J Med 2021;384:1412-1423.

  16. 16. Abu-Raddad LJ, Chemaitelly H, Barrel AA. Effectiveness of the BNT162b2 Covid-xix vaccine against the B.1.1.seven and B.i.351 variants. N Engl J Med 2021;385:187-189.

  17. 17. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-xix vaccines against the B.1.617.2 (delta) variant. Due north Engl J Med 2021;385:585-594.

  18. xviii. Pouwels KB, Pritchard E, Matthews PC, et al. Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Baronial 24, 2021 (https://world wide web.medrxiv.org/content/10.1101/2021.08.xviii.21262237v1). preprint.

  19. 19. Andrews Due north, Tessier East, Stowe J, et al. Duration of protection against mild and astringent disease by Covid-19 vaccines. N Engl J Med 2022;386:340-350.

  20. 20. Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. Partial resistance of SARS-CoV-2 delta variants to vaccine-elicited antibodies and convalescent sera. iScience 2021;24(11):103341-103341.

  21. 21. Goldberg Y, Mandel Thousand, Bar-On YM, et al. Waning immunity of the BNT162b2 vaccine: a nationwide written report from Israel. August xxx, 2021 (https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1). preprint.

  22. 22. Israel A, Merzon Eastward, Schäffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-two infection in a large cohort. August five, 2021 (https://world wide web.medrxiv.org/content/10.1101/2021.08.03.21261496v1). preprint.

  23. 23. Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine: preliminary study. July 31, 2021 (https://www.medrxiv.org/content/ten.1101/2021.07.29.21261317v1). preprint.

  24. 24. Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay 1000, Lopez Bernal J. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-nineteen booster vaccine against covid-19 related symptoms in England: test negative example-control written report. November 15, 2021 (https://www.medrxiv.org/content/10.1101/2021.eleven.15.21266341v1). preprint.

  25. 25. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in State of israel. N Engl J Med 2021;385:1393-1400.

  26. 26. United kingdom Health Security Agency. SARS-CoV-2 variants of business organization and variants under investigation in England: omicron VOC-21NOV-01 (B.i.1.529) update on cases, S gene target failure and hazard cess. December 8, 2021 (https://avails.publishing.service.gov.uk/government/uploads/organization/uploads/attachment_data/file/1039644/Omicron_SGTF_case_update_FINAL.pdf).

  27. 27. UK Health Security Agency. COVID-19 vaccine surveillance study: week 49. 2021 (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1039677/Vaccine_surveillance_report_-_week_49.pdf).

  28. 28. Section of Health & Social Care. JCVI advice on the United kingdom vaccine response to the omicron variant. Independent study. Nov 29, 2021 (https://www.gov.uk/government/publications/uk-vaccine-response-to-the-omicron-variant-jcvi-advice/jcvi-advice-on-the-u.k.-vaccine-response-to-the-omicron-variant).

  29. 29. NHS England. National COVID-19 and flu vaccination programmes. 2021 (https://www.england.nhs.britain/contact-us/privacy-notice/national-flu-vaccination-plan/).

  30. 30. United kingdom of great britain and northern ireland Health Security Agency. COVID-19: the green book, affiliate 14a: coronavirus (COVID-19) vaccination information for public health professionals. 2020 (https://www.gov.united kingdom of great britain and northern ireland/government/publications/covid-19-the-green-book-chapter-14a).

  31. 31. NHS Digital. COVID-19 — high risk shielded patient list identification methodology. 2020 (https://digital.nhs.uk/coronavirus/shielded-patient-list/methodology/rule-logic).

  32. 32. UK Health Security Agency. SARS-CoV-2 variants of business concern and variants nether investigation in England: variant of concern: omicron, VOC-21NOV-01 (B.one.i.529). Technical conference 30. December 3, 2021 (https://avails.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1038404/Technical_Briefing_30.pdf).

  33. 33. Public Health England, GitHub. Stardardised variant definitions. 2021 (https://github.com/phe-genomics/variant_definitions).

  34. 34. U.k. Health Security Agency. SARS-CoV-2 variants of business organization and variants under investigation in England. Technical briefing 31. December 10, 2021 (https://assets.publishing.service.gov.uk/authorities/uploads/system/uploads/attachment_data/file/1042367/technical_briefing-31-10-dec-2021.pdf).

  35. 35. Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-two and variants of concern. Science 2021;374(6572):abm0829-abm0829.

  36. 36. United kingdom Health Security Bureau. SARS-CoV-2 variants of business organization and variants under investigation in England. Technical briefing 34. January 14, 2022 (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1048395/technical-briefing-34-fourteen-january-2022.pdf).

  37. 37. Pavord South, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced allowed thrombocytopenia and thrombosis. N Engl J Med 2021;385:1680-1689.

    • Facebook
    • Twitter
    • LinkedIn
    • Electronic mail
    • Re-create URL
    • Download Citation
    • Permissions
    • Article Alert
    • Reprints